Expands Clade’s pipeline and broadens its platform with:- proprietary gamma/delta (g/d) TCR universal targeting platform technology,- g/d TCR candidate integrated into Clade’s solid tumor pipeline BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Clade Therapeutics (“Clade”), a biopharmaceutical company focused on discovering and delivering engineerable, off-the-shelf, scalable, and consistent stem cell-based medicines, today announced that it has completed the acquisition of Gadeta B.V.

-专有的gamma/delta（g/d）TCR通用靶向平台技术，-集成到Clade实体肿瘤管道中的g/d TCR候选人-波士顿，2023年10月2日（GLOBE NEWSWIRE）-Clade Therapeutics（“Clade”），一家专注于发现和提供可操作，现成，可扩展的生物制药公司，和一致的基于干细胞的药物，今天宣布它已完成收购Gadeta B.V。

(“Gadeta”), a cell therapy company developing innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies for cancer patients. Gadeta is an international R&D company, focused on innovative immunotherapies for cancer. The company developed a proprietary platform to engineer novel g/d TCRs that possess broad tumor targeting capabilities.

（“Gadeta”）是一家为癌症患者开发创新的基于γ/δ（g/d）T细胞受体（TCR）的免疫疗法的细胞疗法公司。Gadeta是一家国际研发公司，专注于癌症的创新免疫疗法。该公司开发了一个专有平台来设计具有广泛肿瘤靶向能力的新型g/d TCR。

These g/d TCRs recognize unique patterns or targets on the surface of cancer cells that signal that they are diseased, thereby specifically targeting cancer cells and sparing healthy cells. The acquisition will provide Clade with preclinical cell therapy programs, g/d TCR discovery engine and a suite of cell enhancement to improve anti-tumor activity of cell therapies.

这些g/d TCR识别癌细胞表面上的独特模式或靶标，表明它们患病，从而特异性靶向癌细胞并保留健康细胞。该收购将为进化枝提供临床前细胞治疗计划，g/d TCR发现引擎和一套细胞增强，以改善细胞疗法的抗肿瘤活性。

The integration of Gadeta’s g/d TCR targeting technology is complementary to Clade’s cellular platform technology and will enhance the development of engineerable, off-the-shelf, scalable, and consistent stem-cell based medicines. Under the terms of the acquisition agreement, Clade has acquired all outstanding shares of Gadeta, making it a wholly owned subsidiary of Clade.

Gadeta g/d TCR靶向技术的整合是对Clade细胞平台技术的补充，将促进可工程化，现成，可扩展和一致的基于干细胞的药物的开发。根据收购协议条款，Clade已收购Gadeta的所有已发行股份，使其成为Clade的合资子公司。

Gadeta shareholders will receive upfront and downstream economics. “Clade is at the forefront of broadening the impact of cell therapy by establishing a more robust cellular platform with stem-cell derived immune c.

Gadeta股东将获得前期和下游经济。“通过建立一个更强大的干细胞衍生免疫细胞平台，进化枝处于扩大细胞治疗影响的最前沿。